Literature DB >> 35962

Antibody response in man following a small intradermal inoculation with Coxiella burnetii phase I vaccine.

M G Peacock, P Fiset, R A Ormsbee, C L Wisseman.   

Abstract

A small inoculum (0.2 microgram) of phase I Coxiella burnetii vaccine given to individuals previously sensitized to CO burnetii elicited a positive skin reaction and a strong IgM phase I antibody response as determined by microagglutination, complement fixation and microimmunofluorescence tests. A similar inoculum administered to nonsensitized individuals did not elitic a skin reaction nor stimulate a recognizable antibody response. Serum from one of these sensitized and skin tested individuals was fractionated by gel filtration methods. The serum and serum fractions were titrated in a mouse seroprotection test using primary chicken embryo cell culture plaque technique as the assay procedure. Results of the mouse seroprotection test indicated that most of the protective activity of the serum was associated with the IgM fraction and that phase I IgM antibody suppressed the growth of C. burnetii in mouse spleen when mixed with the rickettsial suspension prior to inoculation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35962

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  10 in total

1.  Clinical evaluation of a new PCR assay for detection of Coxiella burnetii in human serum samples.

Authors:  G Q Zhang; S V Nguyen; H To; M Ogawa; A Hotta; T Yamaguchi; H J Kim; H Fukushi; K Hirai
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

2.  Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.

Authors:  Ying Peng; Laura Schoenlaub; Alexandra Elliott; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

3.  Formalin-inactivated Coxiella burnetii phase I vaccine-induced protection depends on B cells to produce protective IgM and IgG.

Authors:  Guoquan Zhang; Ying Peng; Laura Schoenlaub; Alexandra Elliott; William Mitchell; Yan Zhang
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

4.  Experimental model for dermal granulomatous hypersensitivity in Q fever.

Authors:  M S Ascher; M A Berman; D Parker; J L Turk
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

Review 5.  Q fever.

Authors:  L G Reimer
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

6.  Serological evaluation of O fever in humans: enhanced phase I titers of immunoglobulins G and A are diagnostic for Q fever endocarditis.

Authors:  M G Peacock; R N Philip; J C Williams; R S Faulkner
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

7.  Immunoglobulin responses to Coxiella burnetii (Q fever): single-serum diagnosis of acute infection, using an immunofluorescence technique.

Authors:  J G Hunt; P R Field; A M Murphy
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

8.  Major Histocompatibility Complex Class II-Restricted, CD4+ T Cell-Dependent and -Independent Mechanisms Are Required for Vaccine-Induced Protective Immunity against Coxiella burnetii.

Authors:  Lindsey Ledbetter; Rama Cherla; Catherine Chambers; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

9.  A longitudinal study of serological responses to Coxiella burnetii and shedding at kidding among intensively-managed goats supports early use of vaccines.

Authors:  Michael Muleme; Angus Campbell; John Stenos; Joanne M Devlin; Gemma Vincent; Alexander Cameron; Stephen Graves; Colin R Wilks; Simon Firestone
Journal:  Vet Res       Date:  2017-09-15       Impact factor: 3.683

10.  Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation.

Authors:  Paul A Beare; Brendan M Jeffrey; Carrie M Long; Craig M Martens; Robert A Heinzen
Journal:  PLoS Pathog       Date:  2018-02-26       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.